chloroquine and derivatives - versus potential COVID-19 treatments - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.10 [0.99, 1.22]< 10%15 studies (15/-)3.9 %some concernlow moderatecrucial-
deaths (time to event analysis only) 1.10 [0.99, 1.23]< 10%2 studies (2/-)3.9 %some concernnot evaluable moderatecrucial-
clinical deterioration 1.03 [0.75, 1.40]< 10%3 studies (3/-)43.7 %some concernnot evaluable moderateimportant-
clinical improvement 1.16 [0.91, 1.49]> 10%3 studies (3/-)88.7 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.29 [0.91, 1.84]> 10%3 studies (3/-)92.5 %some concernnot evaluable moderateimportant-
death or ventilation 1.14 [1.03, 1.25]< 10%3 studies (3/-)0.5 %some concernnot evaluable moderateimportant-
hospital discharge 0.91 [0.54, 1.54]> 10%1 study (1/-)36.2 %some concernnot evaluable moderateimportant-
hospitalization 0.79 [0.42, 1.48]< 10%2 studies (2/-)77.0 %some concernnot evaluable moderateimportant-
PCR-negative conversion 0.46 [0.04, 5.75]> 10%1 study (1/-)27.7 %some concernnot evaluable moderateimportant-
PCR-negative conversion (14-day) 1.09 [0.95, 1.26]> 10%2 studies (2/-)88.8 %some concernnot evaluable moderateimportant-
PCR-negative conversion (7-day) 1.20 [0.60, 2.40]> 10%1 study (1/-)69.7 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 1.33 [0.94, 1.88]> 10%1 study (1/-)94.7 %some concernnot evaluable moderateimportant-
ICU admission 0.56 [0.19, 1.66]< 137%2 studies (2/-)85.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

cardiac arrest 1.92 [0.35, 10.49]< 10%1 study (1/-)22.7 %some concernnot evaluable moderateimportant-
adverse events 1.30 [0.99, 1.69]< 10%8 studies (8/-)2.9 %some concernnot evaluable moderatenon important-
arrhythmia 0.98 [0.02, 50.38]< 10%1 study (1/-)50.4 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.